Proteon Therapeutics Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$42.5M
Proteon Therapeutics General Information
Description
Provider of transformative therapies intended for people with cancer and rare diseases with limited treatment options. The company's portfolio includes an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and also an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease, thereby addressing the needs of patients with the renal and vascular disease.
Contact Information
Website
www.proteontherapeutics.comCorporate Office
- 200 West Street
- Waltham, MA 02451
- United States
Corporate Office
- 200 West Street
- Waltham, MA 02451
- United States
Proteon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 09-Jan-2020 | $42.5M | Completed | Generating Revenue | ||
| 10. Secondary Transaction - Open Market | 26-Jun-2017 | Completed | Generating Revenue | |||
| 9. IPO | 22-Oct-2014 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series D) | 28-May-2014 | Completed | Generating Revenue | |||
| 7. Merger/Acquisition | 18-Mar-2014 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 19-Feb-2014 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 11-Aug-2011 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 28-May-2009 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A1) | 06-Sep-2007 | $12M | $35.6M | Completed | Product Development | |
| 2. Early Stage VC (Series A) | 29-Mar-2006 | $22.6M | $23.6M | Completed | Product Development |
Proteon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 10,909,091 | $0.001000 | $0.08 | $1.1 | $1.1 | 1x | $0.9 | 6.54% |
| Series A | 22,638,465 | $0.001000 | $0.07 | $1 | $1 | 1x | $0.84 | 13.27% |
Proteon Therapeutics Comparisons
Industry
Financing
Details
Proteon Therapeutics Competitors (57)
One of Proteon Therapeutics’s 57 competitors is Pharmacosmos, a Corporate Backed or Acquired company based in Holbaek, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pharmacosmos | Corporate Backed or Acquired | Holbaek, Denmark | ||||
| Mighty Therapeutics | Private Equity-Backed | Needham, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Proteon Therapeutics Patents
Proteon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12551514-B1 | Combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer | Active | 25-Jul-2025 | ||
| WO-2026226668-A1 | Immune priming using non-viable cells of streptococcus pyogenes in cancer therapy | Pending | 23-Apr-2025 | ||
| AU-2024208098-A1 | Combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer | Pending | 09-Jan-2023 | ||
| EP-4648785-A2 | Combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer | Pending | 09-Jan-2023 | ||
| US-20260053867-A1 | Combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer | Pending | 09-Jan-2023 | A61K35/744 |
Proteon Therapeutics Signals
Proteon Therapeutics Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Brooke Private Equity Associates Management | Fund of Funds | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Deutsche Bank | Investment Bank | Minority |
Proteon Therapeutics Acquisitions (1)
Proteon Therapeutics’s most recent deal was a Reverse Merger with Protara Therapeutics. The deal was made on 09-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Protara Therapeutics | 09-Jan-2020 | Reverse Merger | Drug Discovery |
Proteon Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Proteon Therapeutics FAQs
-
When was Proteon Therapeutics founded?
Proteon Therapeutics was founded in 2001.
-
Where is Proteon Therapeutics headquartered?
Proteon Therapeutics is headquartered in Waltham, MA.
-
What is the size of Proteon Therapeutics?
Proteon Therapeutics has 17 total employees.
-
What industry is Proteon Therapeutics in?
Proteon Therapeutics’s primary industry is Drug Discovery.
-
Is Proteon Therapeutics a private or public company?
Proteon Therapeutics is a Private company.
-
What is the current valuation of Proteon Therapeutics?
The current valuation of Proteon Therapeutics is .
-
What is Proteon Therapeutics’s current revenue?
The current revenue for Proteon Therapeutics is .
-
How much funding has Proteon Therapeutics raised over time?
Proteon Therapeutics has raised $185M.
-
Who are Proteon Therapeutics’s investors?
Abingworth, Bessemer Venture Partners, Brooke Private Equity Associates Management, Deerfield Management, and Deutsche Bank are 5 of 16 investors who have invested in Proteon Therapeutics.
-
Who are Proteon Therapeutics’s competitors?
Pharmacosmos, Mighty Therapeutics, Rein Therapeutics, Aldeyra Therapeutics, and Inovio Pharmaceuticals are some of the 57 competitors of Proteon Therapeutics.
-
When was Proteon Therapeutics acquired?
Proteon Therapeutics was acquired on 09-Jan-2020.
-
Who acquired Proteon Therapeutics?
Proteon Therapeutics was acquired by Protara Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process